

Wondering why Slynd is so hard to find at pharmacies? Learn about the Slynd shortage, supply issues, and what you can do to get your prescription filled.
If you've been told your pharmacy is out of Slynd, you're not alone. Thousands of patients across the U.S. have struggled to fill their Slynd prescriptions in recent months. The shortage has left many people scrambling — and understandably frustrated.
In this guide, we'll explain why Slynd is so hard to find, what's causing the supply problems, and what you can do right now to get your birth control.
Slynd is a brand-name progestin-only birth control pill (sometimes called a "mini-pill") that contains 4 mg of Drospirenone. It was FDA-approved for preventing pregnancy and has become popular because it offers a 24-hour missed-pill window — much more forgiving than older progestin-only pills that only allow 3 hours.
Slynd is estrogen-free, making it a top choice for people who can't take estrogen due to migraines with aura, blood clot risk, breastfeeding, or other health reasons.
Slynd is made by Exeltis USA, and there are limited manufacturing facilities producing it. Unlike widely available generics, Slynd's production capacity hasn't always kept up with demand.
As of early 2026, there is no widely available, inexpensive generic version of Drospirenone 4 mg tablets. This means the entire supply depends on one manufacturer, creating a bottleneck.
Slynd has grown in popularity thanks to its forgiving dosing schedule and estrogen-free formula. More prescriptions mean more strain on an already limited supply.
Like many medications, Slynd has been affected by broader pharmaceutical supply chain issues, including raw material sourcing and distribution delays.
Some pharmacies don't regularly stock Slynd because of its higher cost and lower volume compared to generic birth control pills. If your pharmacy doesn't keep it on the shelf, it may need to be special-ordered — adding more delay.
Slynd supply issues have been reported intermittently since 2023. The FDA has listed Drospirenone tablets on its Drug Shortage Database at various points. While availability has improved at times, many patients still report difficulty finding it in stock in 2026.
For the latest shortage details, see our Slynd shortage update for 2026.
MedFinder helps you search for Slynd availability at pharmacies near you in real time. Instead of calling pharmacy after pharmacy, you can check stock online and find where Slynd is available.
If your pharmacy is out of stock, ask them to place a special order with their wholesaler. It may take a few days, but this often works when the shortage is regional rather than nationwide.
Independent pharmacies, mail-order pharmacies, and specialty pharmacies sometimes have stock when big chains don't. Check multiple options.
If you can't find Slynd, there are other progestin-only options available. Read our guide on alternatives to Slynd to learn about your options.
Cost can also be a barrier. If price is part of the problem, check out our guide on how to save money on Slynd.
It's hard to predict exactly when Slynd will be consistently available everywhere. Exeltis has been working to increase supply, and generic competition may eventually help. In the meantime, tools like MedFinder can help you find pharmacies that have it in stock right now.
Slynd is hard to find because of limited manufacturing, no cheap generic, high demand, and supply chain challenges. But you have options — from using MedFinder to searching multiple pharmacies to considering alternative birth control methods. Don't go without contraception just because one pharmacy is out of stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.